Koo, that is correct as far as I can see. Thanks for the link - I also found the following to be quite interesting:

The HR of Repatha treatment for the secondary composite endpoint of heart attack, stroke or cardiovascular death was 0.82 (95 percent CI, 0.72-0.93; p=0.0021) for those with diabetes and 0.78 (95 percent CI, 0.69-0.89; p=0.0002) for those without diabetes.

Thus:

3-point MACE, diabetes: 18% RRR

3-point MACE, without diabets: 22% RRR

Apabetalone is to compete with the 18% RRR, but since Repatha is administered as an injection and since the price of Repatha (an antibody) is an order of magnitude more expensive than a low molecular weight drug, Apabetalone should compare quite favorably to Repathy (assuming that Apabetalone has a reasonably good RRR).

/BKC